M. Hudson

An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers: Safety, Tolerability, and Effects on Glucose, Insulin, and Glucagon Levels

M. Shenouda, K. Hu, Dalal Nesheiwat, 2014, American journal of therapeutics.

Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study

P. Jordaan, K. Hu, Astrid Breitschaft, 2013, Journal of clinical pharmacology.

A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

M. Morse, J. Ramage, B. Jarzab, 2013 .